# Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

> **NCT07338604** · EARLY_PHASE1 · RECRUITING · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Hematolymphoid Malignancies

## Interventions

- **DRUG:** CAR-T cell infusion
- **DRUG:** UTAA07 injection

## Key facts

- **NCT ID:** NCT07338604
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07338604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07338604, "Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07338604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*